An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability

NCT04161482 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Furosemide 80 mg (8 mg/mL)

Sponsor

scPharmaceuticals, Inc.

Collaborators

[object Object]
[object Object]